Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Declines By 14.2%

Aura Biosciences, Inc. (NASDAQ:AURA) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decline of 14.2% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 179,200 shares, the short-interest ratio is presently 6.8 days. Approximately 2.7% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in shares of Aura Biosciences in the 4th quarter valued at approximately $50,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aura Biosciences in the 4th quarter valued at approximately $87,000. ProShare Advisors LLC bought a new stake in shares of Aura Biosciences in the 4th quarter valued at approximately $127,000. Harvest Investment Services LLC bought a new stake in shares of Aura Biosciences in the 4th quarter valued at approximately $133,000. Finally, AlphaQuest LLC bought a new stake in shares of Aura Biosciences in the 4th quarter valued at approximately $136,000. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Trading Up 0.1 %

AURA stock opened at $7.95 on Tuesday. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38. The firm has a market cap of $397.11 million, a P/E ratio of -4.60 and a beta of 0.29. The business’s 50 day moving average is $8.07 and its 200-day moving average is $8.76.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.